Consistent with findings by Thol et al., who reported that SRSF2 mutations were associated with an increased risk of progression to AML [18], we observed a somewhat significant impact of the SRSF2 mutation on the progression time to AML transformation (Figs. 2i and 3d). This evidence concerns the gene SRSF2 and acute myeloid leukemia.